Voyager Therapeutics earnings date
Voyager Therapeutics (VT6) Q4 2024 Earnings Report
DE:VT6 Q4 2024 EPS Results
- Actual EPS
- -EUR 0.53
- Consensus EPS
- -EUR 0.33
- Beat/Miss
- Missed by -EUR 0.20
- One Year Ago EPS
- EUR 1.13
DE:VT6 Q4 2024 Revenue Results
- Actual Revenue
- EUR 5.67M
- Expected Revenue
- EUR 14.99M
- Beat/Miss
- Missed by -EUR 9.31M
- YoY Revenue Growth
- -93.03%
Earnings Announcement Details
- Quarter
- Q4 2024
- Date
- 03/11/2025
- Time
- After Close
- Conference Call
- Tuesday, March 11, 2025
Voyager Therapeutics's next earnings date is estimated for March 9, 2027, based on past reporting schedules.
Q4 2024 Earnings Call Audio
Q4 2024 Earnings Slide Deck
No slide deck is available for this earnings event.
Q4 2024 Earnings Call Summary
The earnings call presented a positive outlook with significant advancements and strong financial positioning. Despite a setback in the SOD1 silencing program, the progress in tau-targeting therapies and potential substantial milestone payments from partnerships highlight a promising future.
During the Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call, the company provided several key metrics and updates about their progress and future plans. Voyager reported $332 million in cash as of the end of 2024 and highlighted potential future milestone payments totaling $8.2 billion, emphasizing the significance of their partnerships as a source of non-dilutive revenue. The company is advancing its tau silencing gene therapy, VY1706, into IND-enabling studies, targeting IND submission in 2026, with promising non-human primate study results showing 50% to 73% knockdown of tau messenger RNA across the brain. Additionally, the anti-tau antibody, VY7523, showed favorable results in a single ascending dose study, with a CSF to serum ratio of 0.3%. Voyager expects initial tau PET data from a multiple ascending dose study in Alzheimer's patients in the second half of 2026. They also noted their $2.9 billion in developmental milestones and guidance extending their cash runway to mid-2027.
- Strong Cash Position and Potential Milestone PaymentsVoyager Therapeutics reported $332 million in cash as of the end of 2024, with potential future milestone payments totaling $8.2 billion from partnerships.
- Advancements in Tau Silencing ProgramThe tau silencing gene therapy program, VY1706, moved forward into IND-enabling studies, showing 50% to 73% knockdown of tau messenger RNA in non-human primate studies.
- Positive Results for Anti-Tau Antibody VY7523VY7523 performed well in a single ascending dose study with no serious adverse events, showing dose-proportional pharmacokinetics and a CSF to serum ratio of 0.3%.
- Promising External Data Supporting Anti-Tau StrategiesUCB's bepranemab demonstrated impact on tau accumulation, and further data from Merck and other companies are anticipated, which may support the potential of tau-targeted therapies.
- Progress in Partnered Programs with NeurocrineTwo programs with Neurocrine are expected to enter the clinic or have an IND filed this year, indicating positive collaboration progress.
DE:VT6 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 09, 2027 | 2026 (Q4) | -0.31- | -0.42 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | -0.38-0.36 | -0.42 | 14.89% (+0.06) | |
| Aug 06, 2026 | 2026 (Q2) | -0.44-0.36 | -0.52 | 29.82% (+0.15) | |
| May 07, 2026 | 2026 (Q1) | -0.50-0.42 | -0.48 | 11.32% (+0.05) | |
| Mar 09, 2026 | 2025 (Q4) | -0.46-0.42 | -0.53 | 22.03% (+0.12) | |
| Nov 10, 2025 | 2025 (Q3) | -0.47-0.42 | -0.14 | -193.75% (-0.28) | |
| Aug 06, 2025 | 2025 (Q2) | -0.48-0.52 | -0.16 | -216.67% (-0.35) | |
| May 06, 2025 | 2025 (Q1) | -0.41-0.48 | -0.18 | -165.00% (-0.30) | |
| Mar 11, 2025 | 2024 (Q4) | -0.33-0.53 | 1.13 | -147.20% (-1.66) | |
| Nov 12, 2024 | 2024 (Q3) | -0.40-0.14 | -0.53 | 72.88% (+0.39) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

